Unity Biotechnology

Unity Biotechnology

A biotechnology company developing drugs and treatments to diminish negative health effects associated with aging.

Unity Biotechnology is a biotechnology company developing drugs and treatments to diminish negative health effects associated with aging that is headquartered in Brisbane, California and was founded in 2009 by Nathaniel David, Jan Van Deursen, Judith Campisi, and Daohong Zhou.

Funding

Convertible note

On May 4, 2009 Unity Biotechnology received a convertible note worth $250,000.

Venture round

On July 15, 2013 Unity Biotechnology completed a venture capital fundraising round with $2 million in funding from undisclosed investors.

Series B

On October 27, 2016 Unity Biotechnology completed their series B funding round with $116 million in funding from Bezos Expeditions (lead investor), WuXi AppTec, Venrock, Mayo Clinic, Ballie Gifford, and ARCH Venture Partners. On August 17, 2017 Unity Biotechnologies closed an additional series B funding round with $35 million in funding from several new investors including: INVUS Opportunities, Three Lakes Partners, Cycad Group, COM Investments, and Pivotal Alpha Limited.

Series C

On March 19, 2018 Unity Biotechnology completed their series C funding round with $55 million in funding from EcoR1 Capital (lead investor), Altitude Life Science Ventures (lead investor), 6 Dimensional Capital (lead investor), Venrock,

The Longevity Fund, Pivotal Alpha Limited, Partner Fund Management, Invus, Founders Fund, Fidelity Management and Research Company, Chestnut Street Ventures, and Ballie Gifford.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Unity Biotechnology Inc funding round, March 2018
Series C round
55,000,000
March 2018
Unity Biotechnology funding round, August 2017
Series B round
151,000,000
August 2017
Invus
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

A Biotech Entrepreneur Aims To Help Us Stay Young While Growing Old

Matthew Herper

Web

Anti-aging startup Unity dives into eye diseases as partnership with Ascentage bears fruit

Amber Tong

Web

Why Jeff Bezos is backing this Silicon Valley scientist who is working on a cure for aging

Andrew Zaleski

Web

Xconomy: Anti-Aging Startup Unity Bio Grabs $55M, Plans First Clinical Trial

Frank Vinluan

Web

Documentaries, videos and podcasts

Title
Date
Link

Drugs to Extend Life - Nathaniel David, CEO of Unity Biotechnology

November 29, 2016

Ned David Catalyst Keynote Address: Dispatches From the Frontiers of Biotechnology

July 20, 2017

This biotech company is trying to stop or reverse age-related diseases

September 13, 2018

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 3, 2020
BioSpace
Proscia®, a leading provider of AI-enabled digital pathology solutions, today announced that UNITY Biotechnology, Inc., a company developing therapeutics to extend health span by slowing, halting, or reversing diseases of aging, has deployed the Concentriq® digital pathology platform to advance its research and development (R&D) pipeline.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.